Sulfobutylether-β-cyclodextrin/chitosan nanoparticles enhance the oral permeability and bioavailability of docetaxel

Drug Development and Industrial Pharmacy

Volumn 39, Issue 7, 2013, Pages 1010-1019

  Wu, Jian ^a,b   Shen, Qi ^b   Fang, Liang ^a  

^a SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

^b SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

Chitosan; Docetaxel; Intestinal absorption; Nanoparticles; Oral bioavailability; Sulfobutylether cyclodextrin

Indexed keywords

BETA CYCLODEXTRIN DERIVATIVE; CHITOSAN DERIVATIVE; DOCETAXEL; NANOCARRIER; SULFOBUTYLETHER BETA CYCLODEXTRIN; TRIPOLYPHOSPHATE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG PENETRATION; GELATION; IN VITRO STUDY; IN VIVO STUDY; MALE; NONHUMAN; RAT; SINGLE DRUG DOSE; SMALL INTESTINE ABSORPTION;

ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC AGENTS; BETA-CYCLODEXTRINS; BIOLOGICAL AVAILABILITY; CHITOSAN; DRUG DELIVERY SYSTEMS; MALE; NANOPARTICLES; PERMEABILITY; RATS; RATS, WISTAR; SPECTROSCOPY, FOURIER TRANSFORM INFRARED; TAXOIDS; X-RAY DIFFRACTION;

EID: 84878880994     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.3109/03639045.2012.694588     Document Type: Article

References (56)

1. Eroles AA, Bafalluy IM, Arnaiz JA. (2009). Stability of docetaxel diluted to 0.3 or 0.9 mg/mL with 0.9% sodium chloride injection and stored in polyolefin or glass containers. Am J Health Syst Pharm, 66:1565-1568.
2. Gao K, Sun J, Liu K, Liu X, He Z. (2008). Preparation and characterization of a submicron lipid emulsion of docetaxel: submicron lipid emulsion of docetaxel. Drug Dev Ind Pharm, 34:1227-1237.
3. Kuppens IE, Bosch TM, van Maanen MJ, Rosing H, Fitzpatrick A, Beijnen JH et al. (2005). Oral bioavailability of docetaxel in combination with OC144-093 (ONT-093). Cancer Chemother Pharmacol, 55:72-78.
4. Ge L, Zhu JB, Xiong F, Ni B. Preparation, characterization and pharmacokinetics of N-palmitoyl chitosan anchored docetaxel liposomes. J Pharm Pharmacol 2007; 59:661-667.
5. Wils P, Phung-Ba V, Warnery A, Lechardeur D, Raeissi S, Hidalgo IJ et al. (1994). Polarized transport of docetaxel and vinblastine mediated by P-glycoprotein in human intestinal epithelial cell monolayers. Biochem Pharmacol, 48:1528-1530.
6. Feng SS, Mei L, Anitha P, Gan CW, Zhou W. (2009). Poly(lactide)- vitamin E derivative/montmorillonite nanoparticle formulations for the oral delivery of Docetaxel. Biomaterials, 30:3297-3306.
7. Cirpanli Y, Bilensoy E, Lale Dogan A, Calis S. (2009). Comparative evaluation of polymeric and amphiphilic cyclodextrin nanoparticles for effective camptothecin delivery. Eur J Pharm Biopharm, 73:82-89.
8. Van Hees T, Piel G, de Hassonville SH, Evrard B, Delattre L. (2002). Determination of the free/included piroxicam ratio in cyclodextrin complexes: comparison between UV spectrophotometry and differential scanning calorimetry. Eur J Pharm Sci, 15:347-353.
9. Yin YM, Cui FD, Mu CF, Choi MK, Kim JS, Chung SJ et al. (2009). Docetaxel microemulsion for enhanced oral bioavailability: preparation and in vitro and in vivo evaluation. J Control Release, 140:86-94.
10. Zheng Y, Zuo Z, Chow AH. (2006). Lack of effect of β-cyclodextrin and its water-soluble derivatives on in vitro drug transport across rat intestinal epithelium. Int J Pharm, 309:123-128.
11. Tønnesen HH, Másson M, Loftsson T. (2002). Studies of curcumin and curcuminoids. XXVII. Cyclodextrin complexation: solubility, chemical and photochemical stability. Int J Pharm, 244:127-135.
12. Krauland AH, Alonso MJ. (2007). Chitosan/cyclodextrin nanoparticles as macromolecular drug delivery system. Int J Pharm, 340:134-142.
13. Teijeiro-Osorio D, Remuñán-López C, Alonso MJ. (2009). Chitosan/cyclodextrin nanoparticles can efficiently transfect the airway epithelium in vitro. Eur J Pharm Biopharm, 71:257-263.
14. Trapani A, Lopedota A, Franco M, Cioffi N, Ieva E, Garcia-Fuentes M et al. (2010). A comparative study of chitosan and chitosan/ cyclodextrin nanoparticles as potential carriers for the oral delivery of small peptides. Eur J Pharm Biopharm, 75:26-32.
15. Prego C, García M, Torres D, Alonso MJ. (2005). Transmucosal macromolecular drug delivery. J Control Release, 101:151-162.
16. Vila A, Sánchez A, Janes K, Behrens I, Kissel T, Vila Jato JL et al. (2004). Low molecular weight chitosan nanoparticles as new carriers for nasal vaccine delivery in mice. Eur J Pharm Biopharm, 57:123-131.
17. Csaba N, Köping-Höggård M, Alonso MJ. (2009). Ionically crosslinked chitosan/tripolyphosphate nanoparticles for oligonucleotide and plasmid DNA delivery. Int J Pharm, 382:205-214.
18. Marchettini P, Stuart OA, Mohamed F, Yoo D, Sugarbaker PH. (2002). Docetaxel: pharmacokinetics and tissue levels after intraperitoneal and intravenous administration in a rat model. Cancer Chemother Pharmacol, 49:499-503.
19. Maestrelli F, Garcia-Fuentes M, Mura P, Alonso MJ. (2006). A new drug nanocarrier consisting of chitosan and hydoxypropylcyclodextrin. Eur J Pharm Biopharm, 63:79-86.
20. Higuchi T, Connors KA. Phase-solubility techniques. Adv Anal Chem Instrum 1965; 4:117-212.
21. Kurozumi M, Nambu N, Nagai T. (1975). Inclusion compounds of non-steroidal antiinflammatory and other slightly water soluble drugs with α- and β-cyclodextrins in powdered form. Chem Pharm Bull, 23:3062-3068.
22. Lee PS, Han JY, Song TW, Sung JH, Kwon OS, Song S et al. (2006). Physicochemical characteristics and bioavailability of a novel intestinal metabolite of ginseng saponin (IH901) complexed with β-cyclodextrin. Int J Pharm, 316:29-36.
23. Bouquet W, Ceelen W, Fritzinger B, Pattyn P, Peeters M, Remon JP et al. (2007). Paclitaxel/β-cyclodextrin complexes for hyperthermic peritoneal perfusion - formulation and stability. Eur J Pharm Biopharm, 66:391-397.
24. Agüerosa M, Ruiz-Gatóna L, Vauthierb C, Bouchemalb K, Espuelasa S, Ponchelb G, Irachea JM. Combined hydroxypropyl-β- cyclodextrin and poly(anhydride) nanoparticles improve the oral permeability of paclitaxel. Eur J Pharm Sci 2009; 38:405-413.
25. Agüeros M, Areses P, Campanero MA, Salman H, Quincoces G, Peñuelas I et al. (2009). Bioadhesive properties and biodistribution of cyclodextrin-poly(anhydride) nanoparticles. Eur J Pharm Sci, 37:231-240.
26. Aktas Y, Andrieux K, Alonso MJ, Calvo P, Gürsoy RN, Couvreur P et al. (2005). Preparation and in vitro evaluation of chitosan nanoparticles containing a caspase inhibitor. Int J Pharm, 298:378-383.
27. Cattani VB, Fiel LA, Jäger A, Jäger E, Colomé LM, Uchoa F et al. (2010). Lipid-core nanocapsules restrained the indomethacin ethyl ester hydrolysis in the gastrointestinal lumen and wall acting as mucoadhesive reservoirs. Eur J Pharm Sci, 39:116-124.
28. Sha X, Fang X. (2004). Transport characteristics of 9-nitrocamptothecin in the human intestinal cell line Caco-2 and everted gut sacs. Int J Pharm, 272:161-171.
29. Zhao L, Wei YM, Zhong XD, Liang Y, Zhang XM, Li W et al. (2009). PK and tissue distribution of docetaxel in rabbits after i.v. administration of liposomal and injectable formulations. J Pharm Biomed Anal, 49:989-996.
30. Lee E, Kim H, Lee IH, Jon S. (2009). In vivo antitumor effects of chitosan-conjugated docetaxel after oral administration. J Control Release, 140:79-85.
31. Huynh L, Grant J, Leroux JC, Delmas P, Allen C. (2008). Predicting the solubility of the anti-cancer agent docetaxel in small molecule excipients using computational methods. Pharm Res, 25:147-157.
32. Fukuda M, Miller DA, Peppas NA, McGinity JW. Influence of sulfobutyl ether-β-cyclodextrin (Captisol®) on the dissolution properties of a poorly soluble drug from extrudates prepared by hot-melt extrusion. Int J Pharm 2008; 350: 118-196.
33. Cserhati T. Interaction of some anticancer drugs with carboxymenthyl-β- cyclodextrin. Int J Pharm 1995;124: 205-211.
34. Song LX, Bai L, Xu XM, He J, Pan SZ. Inclusion complexation, encapsulation interaction and inclusion number in cyclodextrin chemistry. Coord Chem Rev 2009;253: 1276-1284.
35. Mura P, Zerrouk N, Faucci M, Maestrelli F, Chemtob C. (2002). Comparative study of ibuproxam complexation with amorphous β-cyclodextrin derivatives in solution and in the solid state. Eur J Pharm Biopharm, 54:181-191.
36. Nogueiras-Nieto L, Sobarzo-Sánchez E, Gómez-Amoza JL, Otero- Espinar FJ. (2012). Competitive displacement of drugs from cyclodextrin inclusion complex by polypseudorotaxane formation with poloxamer: implications in drug solubilization and delivery. Eur J Pharm Biopharm, 80:585-595.
37. Cirri M, Bragagni M, Mennini N, Mura P. (2012). Development of a new delivery system consisting in "drug-in cyclodextrin-in nanostructured lipid carriers" for ketoprofen topical delivery. Eur J Pharm Biopharm, 80:46-53.
38. Boudad H, Legrand P, Lebas G, Cheron M, Duchêne D, Ponchel G. (2001). Combined hydroxypropyl-β-cyclodextrin and poly(alkylcyanoacrylate) nanoparticles intended for oral administration of saquinavir. Int J Pharm, 218:113-124.
39. Zhang G, Shuang S, Dong Z, Dong C, Pan J. Investigation on the inclusion behavior of neutral red with β-cyclodextrin, hydroxypropyl-β- cyclodextrin and sulfobutylether-β-cyclodextrin. Analytica Chimica Acta 2002;474:189-195
40. Ribeiro LS, Ferreira DC, Veiga FJ. (2003). Physicochemical investigation of the effects of water-soluble polymers on vinpocetine complexation with β-cyclodextrin and its sulfobutyl ether derivative in solution and solid state. Eur J Pharm Sci, 20:253-266.
41. Williams RO 3rd, Mahaguna V, Sriwongjanya M. (1998). Characterization of an inclusion complex of cholesterol and hydroxypropyl-β-cyclodextrin. Eur J Pharm Biopharm, 46:355-360.
42. Ficarra R, Tommasini S, Raneri D, Calabrò ML, Di Bella MR, Rustichelli C et al. (2002). Study of flavonoids/β-cyclodextrins inclusion complexes by NMR, FT-IR, DSC, X-ray investigation. J Pharm Biomed Anal, 29:1005-1014.
43. Aigner Z, Berkesi O, Farkas G, Szabó-Révész P. DSC, X-ray and FTIR studies of a gemfibrozil/dimethyl-β-cyclodextrin inclusion complex produced by co-grinding. J Pharm Bio Ana 2002;57:62-67
44. Spamer E, Müller DG, Wessels PL, Venter JP. (2002). Characterization of the complexes of furosemide with 2-hydroxypropyl-β-cyclodextrin and sulfobutyl ether-7-β-cyclodextrin. Eur J Pharm Sci, 16:247-253.
45. Varma MV, Panchagnula R. (2005). Enhanced oral paclitaxel absorption with vitamin E-TPGS: effect on solubility and permeability in vitro, in situ and in vivo. Eur J Pharm Sci, 25:445-453.
46. Yang T, Cui FD, Choi MK, Cho JW, Chung SJ, Shim CK et al. (2007). Enhanced solubility and stability of PEGylated liposomal paclitaxel: in vitro and in vivo evaluation. Int J Pharm, 338:317-326.
47. Fenyvesi F, Fenyvesi E, Szente L, Goda K, Bacsó Z, Bácskay I et al. (2008). P-glycoprotein inhibition by membrane cholesterol modulation. Eur J Pharm Sci, 34:236-242.
48. Bilensoy E, Gürkaynak O, Dogan AL, Hincal AA. (2008). Safety and efficacy of amphiphilic β-cyclodextrin nanoparticles for paclitaxel delivery. Int J Pharm, 347:163-170.
49. Wang J, Tao X, Zhang Y, Wei D, Ren Y. (2010). Reversion of multidrug resistance by tumor targeted delivery of antisense oligodeoxynucleotides in hydroxypropyl-chitosan nanoparticles. Biomaterials, 31:4426-4433.
50. Werle M, Hoffer M. (2006). Glutathione and thiolated chitosan inhibit multidrug resistance P-glycoprotein activity in excised small intestine. J Control Release, 111:41-46.
51. Palmberger TF, Hombach J, Bernkop-Schnürch A. (2008). Thiolated chitosan: development and in vitro evaluation of an oral delivery system for acyclovir. Int J Pharm, 348:54-60.
52. Sinha VR, Singla AK, Wadhawan S, Kaushik R, Kumria R, Bansal K et al. (2004). Chitosan microspheres as a potential carrier for drugs. Int J Pharm, 274:1-33.
53. Hejazi R, Amiji M. Chitosan-based gastrointestinal delivery systems. J Con Rel 2003; 89:151-165.
54. Bhattarai N, Gunn J, Zhang M. (2010). Chitosan-based hydrogels for controlled, localized drug delivery. Adv Drug Deliv Rev, 62:83-99.
55. Agüeros M, Zabaleta V, Espuelas S, Campanero MA, Irache JM. (2010). Increased oral bioavailability of paclitaxel by its encapsulation through complex formation with cyclodextrins in poly(anhydride) nanoparticles. J Control Release, 145:2-8.
56. Sotthivirat S, Haslam JL, Stella VJ. (2007). Evaluation of various properties of alternative salt forms of sulfobutylether-β- cyclodextrin, (SBE)7M-β-CD. Int J Pharm, 330:73-81.